NextCell's business concept is to develop and commercialize mesenchymal stromal cell products based on the company's patented selection algorithm, primarily for the treatment of autoimmune type 1 diabetes, alongside other types of autoimmune and inflammatory diseases.
NextCell's pivotal drug candidate is ProTrans, developed initially for the treatment of type 1 diabetes. Both safety and efficacy in preserving the patients' ability to produce their own insulin have been demonstrated in clinical drug trials.
Cellaviva is the largest private stem cell bank in Scandinavia. Through Cellaviva, expectant parents are provided with the opportunity to preserve and store their newborn child's stem cells for potential future medical needs of both the child and the family.
Pioneering cell therapy development for thetreatment of autoimmune and inflammatorydisorders.
Lead the way in the development of next generation off-the-shelf cell therapies for treatment of autoimmune and inflammatory disorders.
NextCell was founded in 2014 by CEO Dr. Mathias Svahn, two current board members; Professor Edvard Smith and Hans-Peter Ekre, as well as Dr. Lena Degling Wilkingsson. The company was originally named Cellaviva AB. In 2016, a strategic decision was made to expand the operation and also conduct drug development and stromal cell research. At this point the company changed its name to NextCell Pharma AB.